A 1‐year study of two doses of steroid in combination with methotrexate and chloroquine in the treatment of patients with mild and moderate systemic lupus erythematosus
Identifieur interne : 001D89 ( Main/Exploration ); précédent : 001D88; suivant : 001D90A 1‐year study of two doses of steroid in combination with methotrexate and chloroquine in the treatment of patients with mild and moderate systemic lupus erythematosus
Auteurs : Ting Li [République populaire de Chine] ; Shun-Le Chen [République populaire de Chine] ; Daniel E. Furst [États-Unis] ; Chun-De Bao [République populaire de Chine] ; Li Li [République populaire de Chine] ; Sheng Chen [République populaire de Chine]Source :
- APLAR Journal of Rheumatology [ 0219-0494 ] ; 2006-12.
English descriptors
- Teeft :
- Adverse effect, Adverse effects, Antimalarial, Aplar, Aplar journal, Aseptic, Aseptic necrosis, Chloroquine, Dos, Dosage, Erythematosus, Femoral, Femoral head, Glucocorticoid, Glucocorticosteroids, Infection rate, Lupus, Lupus erythematosus, Lupus nephritis, Main cause, Major organ involvement, Methotrexate, Mild activity, Moderate activity, Moderate disease activity, Prednisone, Prednisone group, Prospective study, Relapse, Renji hospital, Retrospective, Retrospective study, Rheumatol, Rheumatology, Rheumatology department, Same time, Shanghai, Systemic, Systemic lupus erythematosus.
Abstract
Aim: This is a retrospective study on the efficacy and adverse effects of treating mild or moderate systemic lupus erythematosus without major organ involvement using small dosage prednisone combined with MTX and chloroquine (PMC). Methods: As a retrospective 1‐year follow‐up study, clinic outpatients (Rheumatology Department, Renji Hospital, Shanghai, China) were divided by predinisone dose (Group A, prednisone ≤ 0.2 mg/kg/d; Group B prednisone 0.5–0.6 mg/kg/d). All patients (N = 30 per group) were also administered methotrexate (7.5–10 mg/week) and chloroquine (250 mg/d). Efficacy and adverse effects of the two protocol drug regimens were compared. Results: The OUT Score of Group A was reduced from 2.10 ± 1.45 to 0.94 ± 0.73, and Group B from 2.93 ± 2.26 to 1.3 ± 1.29. The treatment was successful and there was no significant difference of efficacy between these two groups. However, the infection rate was much higher in Group B than in Group A (P < 0.001). Most infections occurred in the lung, while infections of the skin were recorded. There were also three patients who presented with Cushing syndrome in Group B. Aseptic necrosis of the femoral head was noted in Group B, but none in Group A. Conclusions: Systemic lupus erythematosus patients with mild or moderate activity, and without major organ involvement, can be controlled well with PMC. Otherwise, it was noted that higher doses of prednisone leads to more infections.
Url:
DOI: 10.1111/j.1479-8077.2006.00243.x
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 000173
- to stream Istex, to step Curation: 000173
- to stream Istex, to step Checkpoint: 000C57
- to stream Main, to step Merge: 001E01
- to stream Main, to step Curation: 001D89
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">A 1‐year study of two doses of steroid in combination with methotrexate and chloroquine in the treatment of patients with mild and moderate systemic lupus erythematosus</title><author><name sortKey="Li, Ting" sort="Li, Ting" uniqKey="Li T" first="Ting" last="Li">Ting Li</name></author><author><name sortKey="Chen, Shun E" sort="Chen, Shun E" uniqKey="Chen S" first="Shun-Le" last="Chen">Shun-Le Chen</name></author><author><name sortKey="Furst, Daniel E" sort="Furst, Daniel E" uniqKey="Furst D" first="Daniel E." last="Furst">Daniel E. Furst</name></author><author><name sortKey="Bao, Chun E" sort="Bao, Chun E" uniqKey="Bao C" first="Chun-De" last="Bao">Chun-De Bao</name></author><author><name sortKey="Li, Li" sort="Li, Li" uniqKey="Li L" first="Li" last="Li">Li Li</name></author><author><name sortKey="Chen, Sheng" sort="Chen, Sheng" uniqKey="Chen S" first="Sheng" last="Chen">Sheng Chen</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:7FC846EAB4C5F24528A2629828C3DEAC6C3B842A</idno><date when="2006" year="2006">2006</date><idno type="doi">10.1111/j.1479-8077.2006.00243.x</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-752M93Z5-3/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">000173</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">000173</idno><idno type="wicri:Area/Istex/Curation">000173</idno><idno type="wicri:Area/Istex/Checkpoint">000C57</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000C57</idno><idno type="wicri:doubleKey">0219-0494:2006:Li T:a:year:study</idno><idno type="wicri:Area/Main/Merge">001E01</idno><idno type="wicri:Area/Main/Curation">001D89</idno><idno type="wicri:Area/Main/Exploration">001D89</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">A 1‐year study of two doses of steroid in combination with methotrexate and chloroquine in the treatment of patients with mild and moderate systemic lupus erythematosus</title><author><name sortKey="Li, Ting" sort="Li, Ting" uniqKey="Li T" first="Ting" last="Li">Ting Li</name><affiliation wicri:level="1"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Rheumatology, Renji Hospital of Shanghai Second Medical University, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Chen, Shun E" sort="Chen, Shun E" uniqKey="Chen S" first="Shun-Le" last="Chen">Shun-Le Chen</name><affiliation wicri:level="1"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Rheumatology, Renji Hospital of Shanghai Second Medical University, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Furst, Daniel E" sort="Furst, Daniel E" uniqKey="Furst D" first="Daniel E." last="Furst">Daniel E. Furst</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>UCLA Medical School – Rheumatology Division, Los Angeles, California</wicri:regionArea><placeName><region type="state">Californie</region></placeName></affiliation></author><author><name sortKey="Bao, Chun E" sort="Bao, Chun E" uniqKey="Bao C" first="Chun-De" last="Bao">Chun-De Bao</name><affiliation wicri:level="1"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Rheumatology, Renji Hospital of Shanghai Second Medical University, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Li, Li" sort="Li, Li" uniqKey="Li L" first="Li" last="Li">Li Li</name><affiliation wicri:level="1"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Rheumatology, Renji Hospital of Shanghai Second Medical University, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author><author><name sortKey="Chen, Sheng" sort="Chen, Sheng" uniqKey="Chen S" first="Sheng" last="Chen">Sheng Chen</name><affiliation wicri:level="1"><country xml:lang="fr">République populaire de Chine</country><wicri:regionArea>Department of Rheumatology, Renji Hospital of Shanghai Second Medical University, Shanghai</wicri:regionArea><wicri:noRegion>Shanghai</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">APLAR Journal of Rheumatology</title><title level="j" type="alt">APLAR JOURNAL OF RHEUMATOLOGY</title><idno type="ISSN">0219-0494</idno><idno type="eISSN">1479-8077</idno><imprint><biblScope unit="vol">9</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="392">392</biblScope><biblScope unit="page" to="396">396</biblScope><biblScope unit="page-count">5</biblScope><publisher>Blackwell Publishing Asia</publisher><pubPlace>Melbourne, Australia</pubPlace><date type="published" when="2006-12">2006-12</date></imprint><idno type="ISSN">0219-0494</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0219-0494</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Adverse effect</term><term>Adverse effects</term><term>Antimalarial</term><term>Aplar</term><term>Aplar journal</term><term>Aseptic</term><term>Aseptic necrosis</term><term>Chloroquine</term><term>Dos</term><term>Dosage</term><term>Erythematosus</term><term>Femoral</term><term>Femoral head</term><term>Glucocorticoid</term><term>Glucocorticosteroids</term><term>Infection rate</term><term>Lupus</term><term>Lupus erythematosus</term><term>Lupus nephritis</term><term>Main cause</term><term>Major organ involvement</term><term>Methotrexate</term><term>Mild activity</term><term>Moderate activity</term><term>Moderate disease activity</term><term>Prednisone</term><term>Prednisone group</term><term>Prospective study</term><term>Relapse</term><term>Renji hospital</term><term>Retrospective</term><term>Retrospective study</term><term>Rheumatol</term><term>Rheumatology</term><term>Rheumatology department</term><term>Same time</term><term>Shanghai</term><term>Systemic</term><term>Systemic lupus erythematosus</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Aim: This is a retrospective study on the efficacy and adverse effects of treating mild or moderate systemic lupus erythematosus without major organ involvement using small dosage prednisone combined with MTX and chloroquine (PMC). Methods: As a retrospective 1‐year follow‐up study, clinic outpatients (Rheumatology Department, Renji Hospital, Shanghai, China) were divided by predinisone dose (Group A, prednisone ≤ 0.2 mg/kg/d; Group B prednisone 0.5–0.6 mg/kg/d). All patients (N = 30 per group) were also administered methotrexate (7.5–10 mg/week) and chloroquine (250 mg/d). Efficacy and adverse effects of the two protocol drug regimens were compared. Results: The OUT Score of Group A was reduced from 2.10 ± 1.45 to 0.94 ± 0.73, and Group B from 2.93 ± 2.26 to 1.3 ± 1.29. The treatment was successful and there was no significant difference of efficacy between these two groups. However, the infection rate was much higher in Group B than in Group A (P < 0.001). Most infections occurred in the lung, while infections of the skin were recorded. There were also three patients who presented with Cushing syndrome in Group B. Aseptic necrosis of the femoral head was noted in Group B, but none in Group A. Conclusions: Systemic lupus erythematosus patients with mild or moderate activity, and without major organ involvement, can be controlled well with PMC. Otherwise, it was noted that higher doses of prednisone leads to more infections.</div></front></TEI><affiliations><list><country><li>République populaire de Chine</li><li>États-Unis</li></country><region><li>Californie</li></region></list><tree><country name="République populaire de Chine"><noRegion><name sortKey="Li, Ting" sort="Li, Ting" uniqKey="Li T" first="Ting" last="Li">Ting Li</name></noRegion><name sortKey="Bao, Chun E" sort="Bao, Chun E" uniqKey="Bao C" first="Chun-De" last="Bao">Chun-De Bao</name><name sortKey="Chen, Sheng" sort="Chen, Sheng" uniqKey="Chen S" first="Sheng" last="Chen">Sheng Chen</name><name sortKey="Chen, Shun E" sort="Chen, Shun E" uniqKey="Chen S" first="Shun-Le" last="Chen">Shun-Le Chen</name><name sortKey="Li, Li" sort="Li, Li" uniqKey="Li L" first="Li" last="Li">Li Li</name></country><country name="États-Unis"><region name="Californie"><name sortKey="Furst, Daniel E" sort="Furst, Daniel E" uniqKey="Furst D" first="Daniel E." last="Furst">Daniel E. Furst</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001D89 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001D89 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:7FC846EAB4C5F24528A2629828C3DEAC6C3B842A
|texte= A 1‐year study of two doses of steroid in combination with methotrexate and chloroquine in the treatment of patients with mild and moderate systemic lupus erythematosus
}}
| This area was generated with Dilib version V0.6.33. |  |